Christina Coughlin

Christina Coughlin, MD, PhD is the former Chief Executive Officer of CytoImmune Therapeutics. Dr. Coughlin joined CytoImmune from Rubius Therapeutics, Inc. where she served as the Chief Medical Officer and led the clinical development, translational medicine and regulatory efforts in the allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the development of autologous CAR-T and TCR-T cellular therapies. Dr. Coughlin served as the Chief Medical Officer for Immunocore, Ltd where she led the development of KimmtrakTM, recently approved for the treatment of metastatic uveal melanoma. Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career including Oncology Asset Team Leader at Pfizer and Clinical Program Team Lead at Novartis. Dr. Coughlin is an oncologist and immunologist, having received her M.D. and Ph.D. from the University of Pennsylvania and completed fellowships in Hematology and Oncology at the Children’s Hospital of Philadelphia and in the Translational Research Group under the direction of Carl June, M.D. at the University of Pennsylvania.